- Home
- SUPN vs ETV Comparison
SUPN vs ETV Comparison
Compare SUPN & ETV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- ETV
- Stock Information
- Founded
- SUPN 2005
- ETV 2005
- Country
- SUPN United States
- ETV United States
- Employees
- SUPN N/A
- ETV N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- ETV Investment Managers
- Sector
- SUPN Health Care
- ETV Finance
- Exchange
- SUPN Nasdaq
- ETV Nasdaq
- Market Cap
- SUPN 2.0B
- ETV 1.7B
- IPO Year
- SUPN 2012
- ETV N/A
- Fundamental
- Price
- SUPN $35.66
- ETV $14.41
- Analyst Decision
- SUPN Hold
- ETV
- Analyst Count
- SUPN 1
- ETV 0
- Target Price
- SUPN $36.00
- ETV N/A
- AVG Volume (30 Days)
- SUPN 285.1K
- ETV 252.5K
- Earning Date
- SUPN 11-04-2024
- ETV 01-01-0001
- Dividend Yield
- SUPN N/A
- ETV 8.75%
- EPS Growth
- SUPN 130.79
- ETV N/A
- EPS
- SUPN 1.07
- ETV N/A
- Revenue
- SUPN $651,972,000.00
- ETV N/A
- Revenue This Year
- SUPN $7.82
- ETV N/A
- Revenue Next Year
- SUPN N/A
- ETV N/A
- P/E Ratio
- SUPN $34.11
- ETV N/A
- Revenue Growth
- SUPN 6.79
- ETV N/A
- 52 Week Low
- SUPN $25.53
- ETV $11.05
- 52 Week High
- SUPN $39.37
- ETV $13.50
- Technical
- Relative Strength Index (RSI)
- SUPN 48.87
- ETV 54.94
- Support Level
- SUPN $35.68
- ETV $14.32
- Resistance Level
- SUPN $37.35
- ETV $14.63
- Average True Range (ATR)
- SUPN 1.01
- ETV 0.13
- MACD
- SUPN -0.18
- ETV -0.02
- Stochastic Oscillator
- SUPN 21.65
- ETV 31.43
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About ETV Eaton Vance Corporation Eaton Vance Tax-Managed Buy-Write Opportunities Fund of Beneficial Interest
Eaton Vance Tax-Managed Buy-Write Opp is a United States-based diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of capital markets, chemicals, banks, biotechnology, media, and other sectors.